Acquisitions are in the air in New England. Here’s what happened in the past week.
—Akamai Technologies (NASDAQ: [[ticker:AKAM]]), the Web content and delivery giant of Cambridge, MA, made a move to tackle Web performance at the browser level, with the acquisition of Ottawa-based Blaze Software. The financial terms of the deal were not disclosed.
—Boston-based Acetylon Pharmaceuticals pulled in a $15 million investment from biotech behemoth Celgene (NASDAQ: [[ticker:CELG]]), which has recently done deals with other New England biotechs like Avila Therapeutics, Acceleron, Foundation Medicine, and Agios.
—Cambridge-based Energy Points emerged with new software enabling businesses to measure their sustainability across different resources. The startup is funded with $3 million from Plan B Ventures.
—Former Biogen Idec head of research Michael Gilman is making a return to the Weston, MA-based drugmaker. Gilman’s Cambridge-based startup Stromedix, founded in 2007 within Atlas Venture, is being acquired by Biogen (NASDAQ: [[ticker:BIIB]]) for $75 million, with potential milestone payments of up to $487.5 million.
—Navinet, the Boston-based provider of real-time communications technology for doctors, hospitals, and health insurers, will be acquired by the health IT firm Lumeris in partnership with three Blue Cross Blue Shield health plans. The deal, whose price tag was undisclosed, is expected to close in 30 days.